Company intelligence / Profile preview

PolyNovo

Port Melbourne, Victoria, Australiapolynovo.com ↗

Ownership: Private
Employees: ~254
Development stage: Other

Overview

PolyNovo’s NovoSorb BTM has been used in over 67,000 patients across 46 countries for burns and complex wound management. The product has demonstrated strong commercial uptake with leading positions in the US and other developed markets. NovoSorb MTX was launched in the US in April 2024 for soft tissue regeneration. A diabetic foot ulcer trial was discontinued due to “indifferent” results.

Therapeutic areas: DermatologyGastroenterologyEndocrinologyOtherCardiovascular
Modalities: DevicePolymer-drug conjugate therapy
Industry: Therapeutic Medical Devices

Partnerships

BARDA (U.S. Biomedical Advanced Research and Development Authority)

Beyond the preview

Go deeper on PolyNovo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PolyNovo.

Explore the full profile